Literature DB >> 3541626

Proliferation of group B streptococci in human amniotic fluid in vitro.

I A Abbasi, V G Hemming, G S Eglinton, T R Johnson.   

Abstract

The group B Streptococcus is one of the most virulent organisms causing perinatal infection. Human amniotic fluid from the second and third trimesters was pooled and analyzed for electrolytes, protein, albumin, zinc, inorganic phosphorus, ferritin, lysozyme, and immunoglobulins. We inoculated replicates of specimens with known virulent strains of group B streptococci (893, 891, and 878) and Escherichia coli (C5) with Todd-Hewitt broth and normal saline solution used as controls. Group B streptococci strains 893 and 891 proliferated rapidly at rates similar to their rates in Todd-Hewitt Broth. Strain 878 grew at a rate slower than that of strains 893 and 891. The amniotic fluid specimens were similar with respect to factors reported as inhibitory to bacterial proliferation. Second- and third-trimester amniotic fluid supports the growth of group B streptococci as well as a culture medium optimized for bacterial growth. Strain-specific variance in group B streptococci growth rates in amniotic fluid may have clinical significance for those at risk for group B streptococci infection.

Entities:  

Mesh:

Year:  1987        PMID: 3541626     DOI: 10.1016/0002-9378(87)90213-4

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  2 in total

1.  Total hemoglobin concentration in amniotic fluid is increased in intraamniotic infection/inflammation.

Authors:  Edi Vaisbuch; Roberto Romero; Offer Erez; Juan Pedro Kusanovic; Francesca Gotsch; Nandor G Than; Shali Mazaki-Tovi; Pooja Mittal; Sam Edwin; Sonia S Hassan
Journal:  Am J Obstet Gynecol       Date:  2008-10       Impact factor: 8.661

2.  Bacterial growth in amniotic fluid is dependent on the iron-availability and the activity of bacterial iron-uptake system.

Authors:  Young-Joon Ahn; Sang-Kee Park; Jae-Wook Oh; Hui Yu Sun; Sung-Heui Shin
Journal:  J Korean Med Sci       Date:  2004-06       Impact factor: 2.153

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.